© Reuters
Eli Lilly (NYSE:) has reported fourth-quarter adjusted earnings per share of $2.49, topping Bloomberg consensus estimates, thanks in part to soaring demand for its diabetes treatment.
Shares in the U.S. drugmaker moved higher in premarket trading on Tuesday.
